News

Stay Informed with Arbele

Discover the latest news and updates from Arbele.

Novel T-cell engager, CDH17 x CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers

Arbele, a clinical-stage biotechnology company focused on the development of novel immunotherapies targeted for advanced gastrointestinal cancers, today announced the positive recommendation from the second meeting of the Data Monitoring Committee (DMC) to continue the A001 Phase I clinical trial evaluating cabotamig (ARB202) in patients with advanced gastrointestinal (GI) cancers without modification to the trial protocol. The DMC, composed of a group of independent experts, arrived at this recommendation after review of the interim safety data of patients enrolled in the A001 trial.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Novel T-cell engager, CDH17 x CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers

Arbele, a clinical-stage biotechnology company focused on the development of novel immunotherapies targeted for advanced gastrointestinal cancers, today announced the positive recommendation from the second meeting of the Data Monitoring Committee (DMC) to continue the A001 Phase I clinical trial evaluating cabotamig (ARB202) in patients with advanced gastrointestinal (GI) cancers without modification to the trial protocol. The DMC, composed of a group of independent experts, arrived at this recommendation after review of the interim safety data of patients enrolled in the A001 trial.

Arbele presented 5 posters in American Association of Cancer Research (AACR) 2024

In the recently concluded American Association of Cancer Research (AACR) meeting, held in San Diego, US, from 5-10 Apr 2024, Arbele presented data from 4 discovery/preclinical programs and 1 diagnostics program in poster presentations.

Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting

Arbele, a clinical-stage biotechnology company developing novel immunotherapies targeted for advanced gastrointestinal cancers, presented early safety data from its first-in-class CDH17xCD3 bispecific T-cell engager antibody, ARB202, at the ASCO Breakthrough conference in Yokohama, Japan.

Arbele celebrates its 7th anniversary as a clinical-stage immunotherapy biotech and the opening of TibTech, its cancer diagnostics subsidiary

Arbele, a biotechnology company dedicated to fighting gastrointestinal cancers, celebrates its 7th anniversary and the opening of Tiberias Technology (TibTech), its accredited lab for cancer screening and in vitro diagnostics, at the Hong Kong Science and Technology Park.

February 9, 2023

Arbele has entered a joint venture with the Chinese Manufacturers' Association of Hong Kong (CMA) with a vision to establish accredited cell banking facilities in Hong Kong and Greater Bay Areas

Arbele has entered a joint venture with the Chinese Manufacturers’ Association of Hong Kong (CMA) on 9 Feb 2023 with a vision to establish accredited cell banking facilities in Hong Kong and Greater Bay Areas. The cell bank will provide cryopreservation services of peripheral blood immune cells from young and adult healthy donors before onset of potential disease and considerably loss of functionality with age.

February 9, 2023

The diagnostic significance of CDH17-positive circulating tumor cells in patients with colorectal cancer

CTC detection by ARB101 antibody could serve as a potential non-invasive approach for CRC detection, progression, and monitoring of treatment response.

August 10, 2022

Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers

Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient in Australia in Phase I Study of ARB202, for the treatment of advanced gastrointestinal cancers patients. Globally, Arbele is the first company exploring the potential of CDH17xCD3 bispecific T-Cell engager antibody in cancer immunotherapy.

Arbele wins Asian Fund for Cancer Research Inaugural 2020 BRACE Award Venture Competition

Arbele has been selected as the winner of the Asian Fund for Cancer Research’s (AFCR) inaugural BRACE Award Venture Competition, a first of its kind program for early stage oncology technology companies located in Asia or focused on cancers prevalent among Asian communities. As a result of its win, the Hong Kong-based company has received US$300,000 in AFCR investment.

Follow Arbele’s Progress

Sign up to receive new information and updates from us.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.